Australia markets close in 1 hour 32 minutes
  • ALL ORDS

    6,849.00
    +77.00 (+1.14%)
     
  • ASX 200

    6,638.50
    +76.90 (+1.17%)
     
  • AUD/USD

    0.7316
    +0.0029 (+0.39%)
     
  • OIL

    43.55
    +0.49 (+1.14%)
     
  • GOLD

    1,823.90
    -13.90 (-0.76%)
     
  • BTC-AUD

    25,099.78
    +68.66 (+0.27%)
     
  • CMC Crypto 200

    368.06
    +6.64 (+1.84%)
     
  • AUD/EUR

    0.6174
    +0.0022 (+0.36%)
     
  • AUD/NZD

    1.0476
    -0.0050 (-0.47%)
     
  • NZX 50

    12,574.31
    +72.57 (+0.58%)
     
  • NASDAQ

    11,905.94
    -0.50 (-0.00%)
     
  • FTSE

    6,333.84
    -17.61 (-0.28%)
     
  • Dow Jones

    29,591.27
    +327.79 (+1.12%)
     
  • DAX

    13,126.97
    -10.28 (-0.08%)
     
  • Hang Seng

    26,474.63
    -11.57 (-0.04%)
     
  • NIKKEI 225

    26,196.64
    +669.27 (+2.62%)
     

IBA – Transparency Notification

IBA SA
·3-min read

(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings)

Louvain-la-Neuve, Belgium, October 20, 2020, 17.45

Summary of the notification

IBA (Ion Beam Application), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on October 20, 2020.

In its notification, Ion Beam Applications SA has notified, that following an introduction of additional notification thresholds in the articles of association, its total holding in IBA SA has crossed upwards the 1% threshold.

Content of the notification

  • Reason for the notification: Introduction of additional notification thresholds in the articles of association

  • Notification by : A parent undertaking or a controlling person

  • Persons subject to the notification requirement:
    Ion Beam Applications SA, Chemin du Cyclotron 3, 1348 Louvain-la-Neuve
    IBA Investments SCRL, Chemin du Cyclotron 3, 1348 Louvain-la-Neuve

  • Date on which the threshold is crossed: 10/03/2020

  • Threshold crossed (in %): 1%

  • Denominator: 37.760.676

  • Notified details: (extract of the received notification form)

A) Voting rights

Previous notification

After the transaction

# of voting rights

# of voting rights

% of voting rights

Holders of voting rights

Linked to securities

Not linked to the securities

Linked to securities

Not linked to the securities

Ion Beam Applications SA

0

127.038

0

0.34%

0.00%

IBA Investments SCRL

0

410.852

0

1.09%

0.00%

Subtotal

0

537.890

1.42%

TOTAL

537.890

0

1.42%

0,00%

B) Equivalent financial instruments

After the transaction

Holder of equivalent financial instruments

Type of financial instrument

Expiration date

Exercise period or date

# of voting rights that may be acquired if the instrument is exercised

% of voting rights

Settlement

TOTAL

0

0.00%

TOTAL (A & B)

# of voting rights

%of voting rights

537.890

1.42%

  • Full chain of controlled undertakings through which the holding is effectively held

IBA Investments SCRL is the subsidiary of Ion Beam Applications SA, wholly owned by the latter.

  • Additional Information

The introduction of new statutory thresholds on March 10, 2020 resulted in this threshold crossing of 1%.

For further information, please contact:

IBA

Elodie Jaumain
Paralegal
+32 10 203 180

legal@iba-group.com

About IBA

IBA (Ion Beam Applications) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

Attachment